Nifty may scale up towards all-time high of 12,400 in Feb series: Axis Securities We expect Smallcap and midcap stocks to perform further and we can see another 3-5% upside in Midcap and smallcap space.
SPARC gets orphan drug designation for Phenobarbital but shares decline 5% The Orphan Drug Designation will grant seven years of US market exclusivity upon approval of Phenobarbital, which is used in treating neonatal seizures.
Stocks in the news: Glenmark Pharma, Ashok Leyland, Lupin, VST Tillers, BEML, SPARC Apar Industries | Ashok Leyland | Prakash Industries | Eveready Industries and JSW Steel are stocks, which are in news today.
An evening walk down D-St: Sensex, Nifty fall for 2nd day in a row; Yes Bank, Tata Motors crash Broader Midcap and Smallcap indices underperformed Sensex, falling 1.32 percent and 1.43 percent, respectively.
Stocks in the news: SPARC, SpiceJet, Alembic Pharma, Dr Reddys Labs, United Spirits, Deepak Nitrite Alembic Pharma | Dr Reddy's Labs | United Spirits | HDIL | Deepak Nitrite | IOL Chemicals and Freshtrop Fruits are stocks which are in the news today.
Sparc - Abraxis Biosciences has filed a complaint in the U.S. Court which alleges that the Spark's filing of new drug application for Taclantis injection as an act of infringement of the Orange Book listed patents for Abraxane. Sentimentally Negative
Podcast | Stock picks of the day: 200-DMA likely to act as tough support for Nifty The long-term 200-DMA levels of 11,130 is going to act as a crucial support area for the Nifty. On the upside, resistance is seen around the 11,400 zone.
A morning walk down Dalal Street | Bounce back can’t be ruled out as Nifty looks oversold The index appears to be getting more pronounced as Nifty closed for the second session below its 200-day exponential moving average (11,296), suggest experts.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.